The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes

被引：6
作者：
Kuang, Zengguang [1 ,2 ,3 ]
Hou, Ningning [1 ,2 ]
Kan, Chengxia [1 ,2 ,3 ]
Han, Fang [4 ]
Qiu, Hongyan [1 ,2 ,3 ]
Sun, Xiaodong [1 ,2 ,3 ]
机构：
[1] Weifang Med Univ, Dept Endocrinol & Metab, Affiliated Hosp, 2428 Yuhe Rd, Weifang 261031, Shandong, Peoples R China
[2] Branch Shandong Prov Clin Res Ctr Diabet & Metab, Weifang, Peoples R China
[3] Weifang Med Univ, Clin Res Ctr, Affiliated Hosp, Weifang, Peoples R China
[4] Weifang Med Univ, Dept Pathol, Affiliated Hosp, Weifang, Peoples R China
来源：
INTERNATIONAL UROLOGY AND NEPHROLOGY | 2023年 / 55卷 / 03期
基金：
中国国家自然科学基金;
关键词：
Diabetic kidney disease; Type 2 diabetes mellitus; GLP-1 receptor agonists; RAAS blockers; SGLT-2; inhibitors; Molecular mechanisms; COTRANSPORTER; 2; INHIBITORS; CARDIOVASCULAR OUTCOMES; BLOOD-PRESSURE; DOUBLE-BLIND; COMBINATION THERAPY; KIDNEY-DISEASE; EMPAGLIFLOZIN; NEPHROPATHY; DAPAGLIFLOZIN; EXENATIDE;
D O I：
10.1007/s11255-022-03355-6
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Diabetic kidney disease is one of the most severe complications of type 2 diabetes mellitus. Patients with diabetic kidney disease have a worse prognosis in terms of mortality and morbidity, compared with patients who have diabetes alone. Strict control of blood pressure and blood glucose is the primary method for prevention of initial kidney damage and delaying further progression of existing damage. Other management approaches include the use of exogenous drugs that can effectively protect the kidneys from diabetes, such as sodium-glucose transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and renin-angiotensin-aldosterone system blockers. These drugs may protect against kidney injury through various molecular mechanisms. This review focuses on renal impairment in patients with type 2 diabetes; it discusses the direct and indirect effects of sodium-glucose transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and renin-angiotensin-aldosterone system blockers on diabetic kidney disease. Finally, it discusses the effects of combination treatment with two or three types of drugs in patients with chronic kidney disease.
引用
收藏
页码：617 / 629
页数：13
相关论文
共 107 条
[11]   Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin [J].
Cherney, David Z. I. ;
Cooper, Mark E. ;
Tikkanen, Ilkka ;
Pfarr, Egon ;
Johansen, Odd Erik ;
Woerle, Hans J. ;
Broedl, Uli C. ;
Lund, Soren S. .
KIDNEY INTERNATIONAL, 2018, 93 (01) :231-244
[12]   Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus [J].
Cherney, David Z. I. ;
Perkins, Bruce A. ;
Soleymanlou, Nima ;
Maione, Maria ;
Lai, Vesta ;
Lee, Alana ;
Fagan, Nora M. ;
Woerle, Hans J. ;
Johansen, Odd Erik ;
Broedl, Uli C. ;
von Eynatten, Maximilian .
CIRCULATION, 2014, 129 (05) :587-597
[13]   Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes [J].
Chilton, R. ;
Tikkanen, I. ;
Cannon, C. P. ;
Crowe, S. ;
Woerle, H. J. ;
Broedl, U. C. ;
Johansen, O. E. .
DIABETES OBESITY & METABOLISM, 2015, 17 (12) :1180-1193
[14]   Diabetes and Hypertension: A Position Statement by the American Diabetes Association [J].
de Boer, Ian H. ;
Bangalore, Sripal ;
Benetos, Athanase ;
Davis, Andrew M. ;
Michos, Erin D. ;
Muntner, Paul ;
Rossing, Peter ;
Zoungas, Sophia ;
Bakris, George .
DIABETES CARE, 2017, 40 (09) :1273-1284
[15]   Impact of CVOTs in primary and secondary prevention of kidney disease [J].
De Cosmo, Salvatore ;
Viazzi, Francesca ;
Piscitelli, Pamela ;
Leoncini, Giovanna ;
Mirijello, Antonio ;
Bonino, Barbara ;
Pontremoli, Roberto .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 157
[16]   Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL [J].
de Zeeuw, D ;
Remuzzi, G ;
Parving, HH ;
Keane, WF ;
Zhang, ZX ;
Shahinfar, S ;
Snapinn, S ;
Cooper, MF ;
Mitch, WE ;
Brenner, BM .
KIDNEY INTERNATIONAL, 2004, 65 (06) :2309-2320
[17]   Critical role of the cAMP-PKA pathway in hyperglycemia-induced epigenetic activation of fibrogenic program in the kidney [J].
Deb, Dilip K. ;
Bao, Riyue ;
Li, Yan Chun .
FASEB JOURNAL, 2017, 31 (05) :2065-2075
[18]   Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor [J].
DeFronzo, Ralph A. .
DIABETES OBESITY & METABOLISM, 2017, 19 (10) :1353-1362
[19]   Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers [J].
Dekkers, Claire C. J. ;
Petrykiv, Sergei ;
Laverman, Gozewijn D. ;
Cherney, David Z. ;
Gansevoort, Ron T. ;
Heerspink, Hiddo J. L. .
DIABETES OBESITY & METABOLISM, 2018, 20 (08) :1988-1993
[20]   Diagnosis and Management of Type 2 Diabetic Kidney Disease [J].
Doshi, Simit M. ;
Friedman, Allon N. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (08) :1366-1373
12345678910